RaDaR Ethics Extension

The RaDaR rare disease registry has been granted a five year recruitment extension from the South West – Central Bristol Research Ethics Committee. This extends recruitment through until 09/10/2024. No changes were made to any of the study documents for this amendment as it was purely to extend recruitment.

For more information please contact nbn-tr.radar@nhs.net

New RaDaR conditions

The Hypokalaemic Alkaloses cohort has been renamed Tubulopathy. It now includes the following conditions:

  • Autoimmune distal renal tubular acidosis
  • Autosomal dominant distal renal tubular acidosis
  • Autosomal recessive distal renal tubular acidosis
  • Autosomal recessive distal renal tubular acidosis
  • Bartter Syndrome type 1
  • Bartter Syndrome type 2
  • Bartter Syndrome type 3
  • Bartter Syndrome type 4
  • Dominant hypophosphatemia with nephrolithiasis or osteoporosis
  • Drug induced Fanconi syndrome
  • Drug induced hypomagnesemia
  • Drug induced Nephrogenic Diabetes Insipidus
  • EAST syndrome (Epilepsy, Ataxia, Sensorineural deafness, Tubulopathy)
  • Familial Hypomagnesaemia with hypercalciuria and nephrocalcinosis CLDN16/19
  • Familial primary hypomagnesemia with hypocalcuria FXYD2
  • Familial primary hypomagnesemia with normocalcuria EGF
  • Familial renal glucosuria SLC5A2
  • Fanconi Renotubular syndrome 1 (FRTS1)
  • Fanconi Renotubular syndrome 2 (FRTS2)
  • Fanconi Renotubular syndrome 3 (FRTS3)
  • Generalized pseudohypoaldosteronism type 1
  • Gitelman Syndrome
  • Heavy metal induced Fanconi syndrome
  • Hereditary renal hypouricemia
  • Hereditary hypophosphatemic rickets with hypercalciuria
  • Isolated autosomal dominant hypomagnesemia, Glaudemans type
  • Liddle syndrome
  • Nephrogenic diabetes insipidus
  • Nephrogenic syndrome of inappropriate antidiuresis
  • Oncogenic osteomalacia
  • Osteopetrosis with renal tubular acidosis
  • Primary hypomagnesemia with secondary hypocalcemia
  • Pseudohypoaldosteronism type 2A
  • Pseudohypoaldosteronism type 2B
  • Pseudohypoaldosteronism type 2C
  • Pseudohypoaldosteronism type 2E
  • Renal pseudohypoaldosteronism type 1

A precise diagnosis will need to be selected when entering these patients in RaDaR.

National survey on rare disease

The Minister for rare disease at the Department of Health and Social Care, Baroness Blackwood, recently announced a national conversation to understand how we can better care for people living with rare disease. 

This survey aims to identify the major challenges faced by rare disease patients and the people and organisations that care for them. The themes identified in the survey will feed into a framework to follow the current UK Strategy on Rare Diseases, which runs until the end of 2020.  

The survey will take around 10-20mins to complete and is open to the rare disease community across the UK, including patients, families and carers, rare disease medical professionals and GPs, clinical academics and industry experts.

The survey can be accessed at:


Tuberous Sclerosis Big Day 2nd November 2019

The Tuberous Sclerosis Association’s (TSA) Big Day 2019 will take place on Saturday 2nd November at the Nottingham Belfry Hotel.

Big Day is an opportunity for everyone in the TSC community to come together – from people living with TSC and their loved ones to clinicians and academics – to share experiences, get to know each other and hear about all-things TSC. You can expect to:

  • Be in an environment where people understand the impact that TSC can have on lives, with significant time allowed for networking
  • Discuss a range of topics, all focused on TSC, from external experts based around the UK
  • Have the opportunity to meet and get to know individuals and families affected by TSC
  • Take part in different workshops and talks, all specially designed to help the TSC community understand and access support, services and care

For more information and booking details please visit:


2019 RaDaR meeting

On Monday 2nd September 2019 a joint patient and clinician event was held at in London to discuss current and future research around the RaDaR rare disease registry, as well as ways to boost patient engagement in research. 

The agenda, a report from the day and pdfs of the presentations can be found below.

RaDaR Meeting Agenda

RaDaR Meeting Report


Current status of RaDaR – Melanie Dillon, RaDaR Operations Officer

Ethics and re-consent – Dr Kate Bramham, Rare Diseases Committee Deputy

ADPKD – Dr Regada El-Damanawi, Research Fellow 

NephroS/NURTuRE – Prof Moin Saleem, Paediatric Nephrologist, Bristol

PREDICT – Dr Kate Bramham Rare Diseases Committee Deputy Chair

ERKNet – Tess Harris, PKD Charity

NIHR BioResource – Dr Kathy Stirrups, Head of Sample Management

NCARDRS Mary Bythell, Head of Rare Disease Registration

NHS Digital – Jackie Shears, Associate Director, Data Acquisitions

Patient Council and information resources – Fiona Loud, Kidney Care Policy Director

Kidney Research UK support – Pete Storey, KRUK Rare Disease Programme Lead

Further research opportunities

As well as taking part in the RaDaR Rare Disease Registry, we recommend that patients who are interested in research visit the NIHR’s new Be Part of Research website which allows you to search for studies by condition and/or location.

Studies that are being led or endorsed by Clinicians involved in RaDaR are advertised on the Patient Information pages for each condition.